Investigation for Clinical Efficacy and Safety of Ipragliflozin 50mg and 100mg on Type II Diabetes

Exclusion Criteria

• •1. Patients with Diabetes Mellitus, Type 1, other types of diabetes or pregnancy diabetes
• •2. Patients with history of severe ketoacidosis, diabetic coma or profound coma for the last 6 months
• •3. Patients with severe infection, in the perioperative period or severe trauma
• •4. Patients with moderate renal insufficiency (serum creatinine level: male with greater than or equal to 1.5mg/dL、female with greater than or equal to1.3mg/dL)
• •5. Patients with severe hepatic impairment (judged by the attending doctor)
• •6. Patients with history of requirement of hospitalization for severe cardiovascular event for the last 6 months of consent
• •7. Patients in pregnancy, breast-feeding, with childbearing potential or plan of pregnancy
• •8. Patients with neuropathic bladder or dysuria
• •9. Patients under treatment with diuretic
• •10. Patients under SGLT2 treatment at the kickoff point of the study
• •11. Patients with a history of hypersensitivity to SGLT2 inhibitors
• •12. Patients who are judged ineligible by the principal investigator